Financing the Next Generation of Safer, More Effective ADCs Through Biopharma Partnerships, Collaborations & Investment Strategies
9:31 am - Monday 8th March 2027
Join leading business development executives, biotech innovators, and investors for an exclusive discussion on the booming ADC dealmaking landscape. In 2026 alone, the ADC sector has continued to attract major investment, highlighted by Gilead’s acquisition of Tubulis GmbH for up to $5 billion and Novartis’ acquisition of Myricx Bio to access its next-generation ADC payload platform and pipeline. Major licensing activity has also continued, including multi-billion-dollar ADC partnerships focused on novel targets, payloads, and conjugation technologies.
Discover what drives licensing decisions, investment strategies, and M&A activity, learn what makes ADC assets stand out to partners, and gain insight into where the market is headed next. As large pharma companies increasingly compete for differentiated ADC platforms and clinical-stage assets, understanding the data, innovation, and risk factors behind successful deals has never been more important.
Speakers Include:
